Invesco
AGRX

Invesco’s Agile Therapeutics AGRX Stock Holding History

Invesco’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11
Closed -$46K – 4069
2021
Q1 		$46K Buy
11
+2
+22% +$10.8K ﹤0.01% 3833
2020
Q4 		$53K Buy
+9
New +$53K ﹤0.01% 3739
2017
Q3 		– Sell
-622
Closed -$4.66M – 3678
2017
Q2 		$4.66M Hold
622
– – ﹤0.01% 2009
2017
Q1 		$3.99M Sell
622
-7
-1% -$35.2K ﹤0.01% 2143
2016
Q4 		$7.17M Hold
629
– – ﹤0.01% 1753
2016
Q3 		$8.78M Buy
629
+291
+86% +$4.15M ﹤0.01% 1585
2016
Q2 		$5.14M Sell
338
-1
-0.3% -$13.7K ﹤0.01% 1903
2016
Q1 		$4.21M Hold
339
– – ﹤0.01% 1998
2015
Q4 		$6.62M Buy
339
+12
+4% +$190K ﹤0.01% 1690
2015
Q3 		$4.41M Buy
327
+7
+2% +$124K ﹤0.01% 1970
2015
Q2 		$5.5M Buy
+320
New +$6.83M ﹤0.01% 1908

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco's AGRX Position: Q2 2021 in Review

Invesco sold out of Agile Therapeutics (AGRX) in Q2 2021, closing a stake of 11 shares — an estimated $46K sold.

Invesco first reported a position in AGRX in Q2 2015 and held it in 11 quarters. The position peaked at $8.78M in Q3 2016. 64 funds tracked by Wall St. Rank hold AGRX as of Q2 2021.

  • Invesco reported no remaining Agile Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Invesco sold 11 Agile Therapeutics shares in Q2 2021, an estimated $46K.
  • Invesco first reported a position in Agile Therapeutics in Q2 2015 and held it in 11 quarters.
  • Invesco's Agile Therapeutics position peaked at $8.78M in Q3 2016.
  • 64 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2021.

Based on Invesco's 13F filing for Q2 2021, filed 17 Aug 2021.